[
    [
        {
            "time": "",
            "original_text": "康泰生物：公司腺病毒载体新冠疫苗已完成临床前研究并提交了临床试验申请",
            "features": {
                "keywords": [
                    "康泰生物",
                    "腺病毒载体",
                    "新冠疫苗",
                    "临床前研究",
                    "临床试验申请"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康泰生物：公司腺病毒载体新冠疫苗已完成临床前研究并提交了临床试验申请",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "康泰生物：公司疫苗产品涵盖国家免疫规划疫苗和非免疫规划疫苗",
            "features": {
                "keywords": [
                    "康泰生物",
                    "疫苗产品",
                    "国家免疫规划",
                    "非免疫规划"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康泰生物：公司疫苗产品涵盖国家免疫规划疫苗和非免疫规划疫苗",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "康泰生物：13价肺炎球菌结合疫苗已申请药品注册批件并完成注册现场检查",
            "features": {
                "keywords": [
                    "康泰生物",
                    "13价肺炎球菌结合疫苗",
                    "药品注册批件",
                    "注册现场检查"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康泰生物：13价肺炎球菌结合疫苗已申请药品注册批件并完成注册现场检查",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "康泰生物：变异株的疫苗研发目前处于临床前研究阶段",
            "features": {
                "keywords": [
                    "康泰生物",
                    "变异株",
                    "疫苗研发",
                    "临床前研究"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康泰生物：变异株的疫苗研发目前处于临床前研究阶段",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "率先分离德尔塔毒株，康泰生物坚持研发创新发展",
            "features": {
                "keywords": [
                    "康泰生物",
                    "德尔塔毒株",
                    "研发创新"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "率先分离德尔塔毒株，康泰生物坚持研发创新发展",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]